文献速递心力衰竭与心肌病

核AGO2通过心肌生酮加重射血分数保留心衰

Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis.
PubMed 文献 · Eur Heart J · 2026-01-01

该研究探讨核内AGO2在西方高脂饮食相关HFpEF中的作用,采用重组腺相关病毒载体干预小鼠心肌AGO2并评估心脏功能。结果显示,敲低AGO2或HMGCS2可减轻高脂饮食诱导的心脏功能障碍,核AGO2过表达则加重心功能障碍。机制涉及AGO2激活HMGCS2转录,并经ATP5MG和UQCR10导致β-OHB过度产生,形成脂毒性与酮毒性正反馈环。

要点

  • 高脂饮食模型中核AGO2通过激活HMGCS2促进心肌β-OHB过度产生。
  • 敲低AGO2或HMGCS2可减轻高脂饮食相关心脏舒张功能障碍。
  • 核AGO2而非胞质AGO2过表达会加重高脂饮食诱导的心功能障碍。

核心结论

  • 长期西方高脂饮食可模拟HFpEF的部分关键特征,表现为舒张功能障碍且左心室射血分数>50%。
  • AGO2/HMGCS2通路在心脏中连接脂毒性与酮毒性,为代谢紊乱相关HFpEF提供潜在干预策略。

研究设计与样本

  • 研究使用重组腺相关病毒血清型9载体在小鼠中干预AGO2或HMGCS2表达。
  • 机制探索采用超声心动图、导管测压、蛋白质组学、染色质免疫沉淀、荧光素酶实验、Western blotting、免疫荧光、Seahorse实验及β-OHB和ATP测定。

主要发现

  • 敲低AGO2可减轻高脂饮食诱导的心脏功能障碍,AGO2可激活HMGCS2转录。
  • ATP5MG和UQCR10被鉴定为AGO2/HMGCS2介导β-OHB过度产生的关键下游靶点。
  • 研究发现PKCα-ERK-EGR1-AGO2-HMGCS2轴参与脂肪酸诱导心肌细胞功能障碍的启动。
  • 脂肪酸诱导中存在脂毒性与酮毒性之间的正反馈环。

临床怎么用

  • 核AGO2/HMGCS2通路可作为代谢紊乱相关HFpEF的潜在治疗靶点进行后续验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: With the prevalence of Western-style high-fat diet (HFD), the incidence of heart failure with preserved ejection fraction (HFpEF) is gradually increasing. Recent studies suggested that microRNAs (miRNAs) located in different subcellular organelles could regulate lipid metabolism and cardiac function. However, the functional property of subcellular argonaute 2 (AGO2), the core member of miRNA machinery, remained elusive in HFD-related HFpEF. METHODS: The causal role of nuclear AGO2 in inducing cardiac dysfunction was revealed with a recombinant adeno-associated virus (serotype 9) vector. The underlying mechanisms were explored with echocardiography, catheter manometer system, proteomics analyses, chromatin immunoprecipitation assays, luciferase assays, Western blotting, immunofluorescence, seahorse assays, β-hydroxybutyrate (β-OHB), and ATP measurements. RESULTS: Knockdown of AGO2 attenuated HFD-induced cardiac dysfunction. Mechanistically, AGO2 could activate the transcription of HMGCS2. Knockdown of either cardiac AGO2 or HMGCS2 protected against HFD-induced cardiac dysfunction. Subsequent high-through profiling further identified ATP5MG and UQCR10 as the key downstream targets for AGO2/HMGCS2 mediated β-OHB over-production, and a feed forward loop involving lipo-toxicity and ketone-toxicity was discovered. Furthermore, a PKCα-ERK-EGR1-AGO2-HMGCS2 axis in the initiation of fatty acid-induced cardiomyocyte dysfunction was revealed. Importantly, overexpressing of nuclear AGO2 rather than cytosolic AGO2 exacerbated the HFD-induced cardiac dysfunction in mice. CONCLUSIONS: These findings uncover that long-term Western-style HFD treatment captures some critical characteristics of HFpEF, characterized by diastolic dysfunction with left ventricular ejection fraction >50%. AGO2/HMGCS2 pathway links lipo-toxicity to ketone-toxicity in the heart, which provides new mechanistic insights and suggests a potential strategy to develop treatments against metabolism disorder-related HFpEF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Jin, Tang, Zhan, et al. Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis. Eur Heart J. 2026. PMID: 41784225. doi:10.1093/eurheartj/ehag067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。